CN102441057A - 一种养血清脑颗粒的hplc指纹图谱检测方法 - Google Patents
一种养血清脑颗粒的hplc指纹图谱检测方法 Download PDFInfo
- Publication number
- CN102441057A CN102441057A CN2010105061215A CN201010506121A CN102441057A CN 102441057 A CN102441057 A CN 102441057A CN 2010105061215 A CN2010105061215 A CN 2010105061215A CN 201010506121 A CN201010506121 A CN 201010506121A CN 102441057 A CN102441057 A CN 102441057A
- Authority
- CN
- China
- Prior art keywords
- detection method
- keli
- yangxue qingnao
- blood
- refreshing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 20
- 238000004128 high performance liquid chromatography Methods 0.000 title claims abstract description 10
- 238000012360 testing method Methods 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 19
- 238000007639 printing Methods 0.000 claims description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000012071 phase Substances 0.000 claims description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 239000007791 liquid phase Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 21
- 239000000523 sample Substances 0.000 abstract description 15
- 239000012488 sample solution Substances 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 238000005303 weighing Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 24
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 14
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 14
- 239000012567 medical material Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 235000001785 ferulic acid Nutrition 0.000 description 8
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 8
- 229940114124 ferulic acid Drugs 0.000 description 8
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 8
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 8
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 7
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 7
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 7
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 7
- 229960003321 baicalin Drugs 0.000 description 7
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 7
- 235000004883 caffeic acid Nutrition 0.000 description 7
- 229940074360 caffeic acid Drugs 0.000 description 7
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 7
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 7
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 241001251200 Agelas Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000217407 Margaritifera Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Landscapes
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010506121.5A CN102441057B (zh) | 2010-10-14 | 2010-10-14 | 一种养血清脑颗粒的hplc指纹图谱检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010506121.5A CN102441057B (zh) | 2010-10-14 | 2010-10-14 | 一种养血清脑颗粒的hplc指纹图谱检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102441057A true CN102441057A (zh) | 2012-05-09 |
CN102441057B CN102441057B (zh) | 2014-12-03 |
Family
ID=46004317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010506121.5A Active CN102441057B (zh) | 2010-10-14 | 2010-10-14 | 一种养血清脑颗粒的hplc指纹图谱检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102441057B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103630614A (zh) * | 2012-08-22 | 2014-03-12 | 天士力制药集团股份有限公司 | 养血清脑颗粒的高效液相色谱检测方法 |
CN105301140A (zh) * | 2015-11-25 | 2016-02-03 | 江苏康缘药业股份有限公司 | 一种注射用活血通络成分检测方法 |
CN107917966A (zh) * | 2016-10-08 | 2018-04-17 | 天士力医药集团股份有限公司 | 一种养血清脑制剂的检测方法 |
CN108872432A (zh) * | 2018-07-11 | 2018-11-23 | 南京海昌中药集团有限公司 | 延胡索生品及其炮制品的质量检测方法 |
CN110967416A (zh) * | 2018-09-29 | 2020-04-07 | 天津天士力现代中药资源有限公司 | 一种养血清脑水提浸膏中细辛脂素的测定方法 |
CN113720954A (zh) * | 2021-09-18 | 2021-11-30 | 安徽中医药大学第一附属医院(安徽省中医院) | 一种智脑胶囊指纹图谱建立方法及质量评价方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1552416A (zh) * | 2003-06-03 | 2004-12-08 | 天津天士力制药股份有限公司 | 一种药物组合物在制备治疗高血压病药物中的应用 |
WO2007022710A1 (fr) * | 2005-08-24 | 2007-03-01 | Tianjin Tasly Pharmaceutical Co. Ltd. | Compositions a base de medecine chinoise pour le traitement de cephalees, formulations et procedes de preparation |
-
2010
- 2010-10-14 CN CN201010506121.5A patent/CN102441057B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1552416A (zh) * | 2003-06-03 | 2004-12-08 | 天津天士力制药股份有限公司 | 一种药物组合物在制备治疗高血压病药物中的应用 |
WO2007022710A1 (fr) * | 2005-08-24 | 2007-03-01 | Tianjin Tasly Pharmaceutical Co. Ltd. | Compositions a base de medecine chinoise pour le traitement de cephalees, formulations et procedes de preparation |
Non-Patent Citations (1)
Title |
---|
秦昉等: "液相色谱- 质谱联用测定养血清脑颗粒中芍药苷的含量", 《中国医院药学杂志》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103630614A (zh) * | 2012-08-22 | 2014-03-12 | 天士力制药集团股份有限公司 | 养血清脑颗粒的高效液相色谱检测方法 |
CN105301140A (zh) * | 2015-11-25 | 2016-02-03 | 江苏康缘药业股份有限公司 | 一种注射用活血通络成分检测方法 |
CN107917966A (zh) * | 2016-10-08 | 2018-04-17 | 天士力医药集团股份有限公司 | 一种养血清脑制剂的检测方法 |
CN107917966B (zh) * | 2016-10-08 | 2022-02-18 | 天士力医药集团股份有限公司 | 一种养血清脑制剂的检测方法 |
CN108872432A (zh) * | 2018-07-11 | 2018-11-23 | 南京海昌中药集团有限公司 | 延胡索生品及其炮制品的质量检测方法 |
CN110967416A (zh) * | 2018-09-29 | 2020-04-07 | 天津天士力现代中药资源有限公司 | 一种养血清脑水提浸膏中细辛脂素的测定方法 |
CN110967416B (zh) * | 2018-09-29 | 2023-02-21 | 天津天士力现代中药资源有限公司 | 一种养血清脑水提浸膏中细辛脂素的测定方法 |
CN113720954A (zh) * | 2021-09-18 | 2021-11-30 | 安徽中医药大学第一附属医院(安徽省中医院) | 一种智脑胶囊指纹图谱建立方法及质量评价方法 |
CN113720954B (zh) * | 2021-09-18 | 2022-02-11 | 安徽中医药大学第一附属医院(安徽省中医院) | 一种智脑胶囊指纹图谱建立方法及质量评价方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102441057B (zh) | 2014-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101850070B (zh) | 中药唐草片的检测方法 | |
CN102441057A (zh) | 一种养血清脑颗粒的hplc指纹图谱检测方法 | |
CN109490437B (zh) | 白芍的指纹图谱检测方法 | |
CN110376294B (zh) | 一种瓜蒌配方颗粒指纹图谱的构建方法 | |
CN101703611B (zh) | 当归益血口服液的质量检测方法 | |
CN101961381A (zh) | 一种丹参配方颗粒的制备方法及其检测方法 | |
CN101028388B (zh) | 一种治疗眼疾近视及视疲劳中药制剂的质量检测方法 | |
CN107356684A (zh) | 决明子指纹图谱的检测方法 | |
CN101444589A (zh) | 一种分清五淋丸的质量标准及其检验方法 | |
CN101966223A (zh) | 一种复方扶芳藤制剂的指纹图谱检测方法 | |
CN111175429B (zh) | 杀菌止痒洗剂指纹图谱的建立方法 | |
CN101513467A (zh) | 皮肤病血毒制剂的质量控制方法 | |
CN100437112C (zh) | 一种治疗中老年眼部疾病中药制剂的质量检测方法 | |
CN103245733A (zh) | 一种藿香正气滴丸鉴定方法 | |
CN107727754A (zh) | 一种小金制剂的hplc指纹图谱检测方法 | |
CN102778516A (zh) | 一种大黄蛰虫胶囊指纹图谱鉴别方法 | |
CN115902050A (zh) | 一种中药复方制剂高效液相指纹图谱的建立方法及应用 | |
CN110274970A (zh) | 融差指纹图谱的建立方法及其在益血生胶囊质控中的应用 | |
CN102590423B (zh) | 川芎茶调颗粒制剂指纹图谱的测定方法 | |
CN113341007A (zh) | 一种基于hplc特征图谱的枣仁安神胶囊全药味多成分含量测定方法 | |
CN101028474B (zh) | 一种具有壮阳益肾功能中药制剂补肾康乐的质量检测方法 | |
CN101008632A (zh) | 五味子水煎液的hplc标准指纹图谱及其建立方法 | |
CN102841154B (zh) | 一种甘芍消渴片的质量检测方法 | |
CN108614066A (zh) | 一种治疗冠心病的中药药物组合物检测方法 | |
CN112666278A (zh) | 华佗再造丸中士的宁的限量检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TIANJIN TIANSHILI PHARMACEUTICAL CO., LTD. TO: TASLY PHARMACEUTICAL GROUP CO., LTD. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170829 Address after: 300402 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: Tianjin Tasly Modern Chinese Medicine Resource Co., Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
TR01 | Transfer of patent right |